Restoration of Peripheral Intermediate and Classical Monocytes Expressing HLA-DR in Patients With Lung Adenocarcinoma After Platinum-Based Chemotherapy

Technol Cancer Res Treat. 2018 Jan 1:17:1533033818764720. doi: 10.1177/1533033818764720.

Abstract

Lung adenocarcinoma represents one of the lung cancer subtypes with major prevalence. Accumulating evidence indicates that the immune system plays an important role in the evolution of the neoplastic process; additionally, several reports suggest that chemotherapy has an immunomodulatory effect. In order to identify the peripheral subpopulations of leukocytes that may change after chemotherapy, we evaluated several peripheral immune subpopulations of monocytes and lymphocytes by multicolor flow cytometry. In addition, we also measured cytokines and growth factors on plasma in order to evaluate the pro-inflammatory context in patients with lung adenocarcinoma after chemotherapy. We found that HLA-DR+ classical and intermediate monocytes were decreased in patients before chemotherapy, compared to controls. After chemotherapy, the relative percentage of those subpopulations was restored. In addition, interleukin 1β, interleukin 12, and interleukin 5 were increased after chemotherapy compared to prechemotherapy levels, while MIP-1β was decreased.

Keywords: chemotherapy; immune cell subpopulations; lung adenocarcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung / drug therapy
  • Adenocarcinoma of Lung / immunology*
  • Adenocarcinoma of Lung / mortality
  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Female
  • HLA-DR Antigens / immunology
  • Humans
  • Kaplan-Meier Estimate
  • Leukocytes, Mononuclear / drug effects*
  • Leukocytes, Mononuclear / immunology*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / immunology*
  • Lung Neoplasms / mortality
  • Male
  • Middle Aged
  • Platinum Compounds / therapeutic use
  • Prognosis
  • T-Lymphocyte Subsets / drug effects*
  • T-Lymphocyte Subsets / immunology*

Substances

  • Antineoplastic Agents
  • HLA-DR Antigens
  • Platinum Compounds